Bernstein Liebhard LLP Reminds Aquestive Shareholders of Lawsuit

Class action lawsuit alleges Aquestive Therapeutics misled investors about drug pipeline.

Apr. 2, 2026 at 6:33pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a broken glass beaker, a crumpled financial document, and a broken pen on a clean, monochromatic background, conceptually representing the breakdown of trust and transparency in the pharmaceutical industry.A shattered symbol of the pharmaceutical industry's accountability crisis.NYC Today

Bernstein Liebhard LLP, a national law firm, has filed a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) on behalf of shareholders. The lawsuit alleges that Aquestive Therapeutics made false and misleading statements about the progress and prospects of its drug pipeline, leading to investor losses.

Why it matters

Aquestive Therapeutics is a pharmaceutical company focused on developing drugs for central nervous system (CNS) disorders and other conditions. The outcome of this lawsuit could have significant financial implications for the company and impact investor confidence in its future.

The details

The class action lawsuit alleges that Aquestive Therapeutics misled investors by providing overly optimistic updates about the development of its drug candidates, particularly its lead product Libervant. The lawsuit claims the company failed to disclose setbacks and delays in the regulatory approval process, leading to a decline in the company's stock price when the issues were eventually revealed.

  • The lawsuit was filed on April 2, 2026.

The players

Bernstein Liebhard LLP

A national law firm that specializes in class action lawsuits and has filed the lawsuit against Aquestive Therapeutics on behalf of shareholders.

Aquestive Therapeutics, Inc.

A pharmaceutical company focused on developing drugs for central nervous system (CNS) disorders and other conditions, which is the target of the class action lawsuit.

Got photos? Submit your photos here. ›

What’s next

The lawsuit is in the early stages, and the court will determine the next steps in the legal process.

The takeaway

This lawsuit highlights the importance of pharmaceutical companies providing accurate and transparent information to investors about the progress of their drug pipelines. Investors will be closely watching the outcome of this case and its potential impact on Aquestive Therapeutics' future.